Rankings
▼
Calendar
APLS Q3 2023 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
APLS
Apellis Pharmaceuticals, Inc.
$3B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$110M
+400.5% YoY
Gross Profit
$88M
79.7% margin
Operating Income
-$137M
-124.2% margin
Net Income
-$140M
-127.0% margin
EPS (Diluted)
$-1.17
QoQ Revenue Growth
+16.2%
Cash Flow
Operating Cash Flow
-$169M
Free Cash Flow
-$169M
Stock-Based Comp.
$22M
Balance Sheet
Total Assets
$818M
Total Liabilities
$586M
Stockholders' Equity
$232M
Cash & Equivalents
$452M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$110M
$22M
+400.5%
Gross Profit
$88M
$21M
+325.6%
Operating Income
-$137M
-$153M
+10.4%
Net Income
-$140M
-$191M
+26.7%
Revenue Segments
Product
$99M
90%
Licensing And Other Revenue
$11M
10%
← FY 2023
All Quarters
Q4 2023 →